Cardiol Therapeutics Inc.
CRDLNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CRDL. That does not mean none is planned.
Get an email about CRDL's next catalysts
Track Cardiol Therapeutics (CRDL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
CRDL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.05 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CardiolRx | Phase 3 | Acute Myocarditis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Cardiol Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Cardiol Therapeutics Inc.'s (CRDL) pipeline across Phase 3. Its lead program is CardiolRx (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiol Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cardiol Therapeutics Inc. (CRDL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CRDL biotech catalysts?→
Add CRDL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiol Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.